AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3881242 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 334
Study 3881242 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 334
Study 3881242 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 334
Study 3881242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 334
Study 30813779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 40
Study 30813779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Number of subjects: 40
Study 30948622 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary-flow data-independent acquisition (DIA) mass spectrometry
Number of subjects: 1508
Study 29153873 — intervention group
Group type: EXPERIMENTAL
Intervention: BeatIt (behavioural activation intervention)
Number of subjects: 161
Study 29153873 — intervention group
Group type: COMPARATOR
Intervention: StepUp (guided self-help intervention)
Number of subjects: 161
Study 25499305 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA + PTA
Number of subjects: 250
Study 25499305 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 250
Study 23452711 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT), used twice a day for two months
Number of subjects: 35
Study 23452711 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 35
Study 21105846 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ
Number of subjects: 40
Study 21105846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex
Number of subjects: 40
Study 21105846 — intervention group
Group type: EXPERIMENTAL
Intervention: Endofill
Number of subjects: 40
Study 21105846 — intervention group
Group type: COMPARATOR
Intervention: Control group (gutta‐percha cone only)
Number of subjects: 40
Study 18848470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of oral glucosamine sulphate once daily for 2 years
Number of subjects: 222
Study 18848470 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 2 years
Number of subjects: 222
Study 17128343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF)
Number of subjects: 1570
Study 17128343 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC)
Number of subjects: 1570
Study 17128343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) among HIV-infected women
Number of subjects: 1570
Study 17128343 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-infected women
Number of subjects: 1570
Study 17128343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) among HIV-uninfected women
Number of subjects: 1570
Study 17128343 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-uninfected women
Number of subjects: 1570
Study 17128343 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tinidazole plus fluconazole (TF) followed by metronidazole plus vaginal clotrimazole (MC) as second-line treatment
Number of subjects: 1570
Study 15090119 — intervention group
Group type: EXPERIMENTAL
Intervention: All Stars program
Number of subjects: 14
Study 11721720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (10 mg bolus + 10 mg/hour for 3 days)
Number of subjects: 90
Study 11721720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9207470 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19+ B cells
Number of subjects: 521
Study 8256988 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1700 mg of calcium carbonate daily)
Number of subjects: 118
Study 8256988 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progesterone-calcium (0.625 mg conjugated equine estrogens, 10 mg progesterone, and 1700 mg elemental calcium daily)
Number of subjects: 118
Study 8256988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 3300974 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide 5‐mononitrate (acute administration)
Number of subjects: 14
Study 3300974 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide 5‐mononitrate (2 months treatment, 20 mg three times daily)
Number of subjects: 14
Study 3300974 — intervention group
Group type: COMPARATOR
Intervention: placebo (acute administration)
Number of subjects: 14
Study 31914620 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise twice-a-day
Number of subjects: 0
Study 31914620 — intervention group
Group type: COMPARATOR
Intervention: Once-daily exercise
Number of subjects: 0
Study 31129103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hua-Shan Grading of Upper Extremity (H-S grading)
Number of subjects: 64
Study 27988144 — intervention group
Group type: EXPERIMENTAL
Intervention: EUC plus CAP
Number of subjects: 377
Study 24584608 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight Tenckhoff catheters (SCs)
Number of subjects: 189
Study 24584608 — intervention group
Group type: COMPARATOR
Intervention: Coiled Tenckhoff catheters (CCs)
Number of subjects: 189
Study 24088004 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program
Number of subjects: 80
Study 24088004 — intervention group
Group type: COMPARATOR
Intervention: No educational program
Number of subjects: 80
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual tumor measurements (TM) at 12 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria (three-level) at 12 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria (two-level) at 12 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual TM at 24 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria (three-level) at 24 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria (two-level) at 24 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual TM in patients with WHO status of response at 12 weeks
Number of subjects: 1188
Study 21632455 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual TM in patients with stable disease or progression at 12 weeks
Number of subjects: 1188
Study 19225758 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular passive ROM exercise (PROME) by a physical therapist
Number of subjects: 50
Study 19225758 — intervention group
Group type: COMPARATOR
Intervention: No PROME (control knee)
Number of subjects: 50
Study 16681817 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole 1% cream applied once a day for 2 weeks, followed by placebo for 2 weeks.
Number of subjects: 511
Study 16681817 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% cream applied once a day for 4 weeks.
Number of subjects: 511
Study 16681817 — intervention group
Group type: EXPERIMENTAL
Intervention: Luliconazole 1% cream
Number of subjects: 511
Study 16681817 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% cream
Number of subjects: 511
Study 16681817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 511
Study 15080791 — intervention group
Group type: EXPERIMENTAL
Intervention: BXL-628
Number of subjects: 0
Study 12434826 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch (forearm touched for 1 to 2 seconds)
Number of subjects: 227
Study 12434826 — intervention group
Group type: COMPARATOR
Intervention: No touch (forearm not touched)
Number of subjects: 227
Study 9771305 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 120
Study 9771305 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms kg‐1
Number of subjects: 120
Study 9771305 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 100 micrograms kg‐1
Number of subjects: 120
Study 9771305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8554863 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and/or discussion for newly detected problems
Number of subjects: 249
Study 8554863 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and/or discussion for known problems
Number of subjects: 249
Study 8554863 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for further management for newly detected problems
Number of subjects: 249
Study 8554863 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for further management for known problems
Number of subjects: 249
Study 8554863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of health status
Number of subjects: 249
Study 2375514 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in O2
Number of subjects: 51
Study 2375514 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane with 25% N2O
Number of subjects: 51
Study 2375514 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane with 50% N2O
Number of subjects: 51
Study 2375514 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane with 75% N2O
Number of subjects: 51
Study 405123 — intervention group
Group type: EXPERIMENTAL
Intervention: Synoviorthesis by erbium-169
Number of subjects: 201
Study 405123 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular placebo
Number of subjects: 201
Study 405123 — intervention group
Group type: COMPARATOR
Intervention: Corticotherapy
Number of subjects: 201
Study 30109456 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-test kits announced via text message sent three times
Number of subjects: 2196
Study 30109456 — intervention group
Group type: COMPARATOR
Intervention: General HIV testing announced via text message sent three times (enhanced SOC)
Number of subjects: 2196
Study 30109456 — intervention group
Group type: COMPARATOR
Intervention: General HIV testing announced via text message sent one time (traditional SOC)
Number of subjects: 2196
Study 29067906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBCs stored for ≤ 7 days
Number of subjects: 1211
Study 29067906 — intervention group
Group type: COMPARATOR
Intervention: Standard-aged RBCs
Number of subjects: 1211
Study 24684520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (8-week treatment as an adjunct to usual psoriasis therapy)
Number of subjects: 29
Study 24684520 — intervention group
Group type: COMPARATOR
Intervention: Usual psoriasis therapy alone (Control group)
Number of subjects: 29
Study 24423341 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 69
Study 24423341 — intervention group
Group type: EXPERIMENTAL
Intervention: CD163 mRNA expression
Number of subjects: 69
Study 24423341 — intervention group
Group type: COMPARATOR
Intervention: Dietary intervention (very low-calorie diet)
Number of subjects: 69
Study 23427387 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiutengzhuyu tablets taken orally for 25 days
Number of subjects: 115
Study 23427387 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine infusion of 5 mg dexamethasone sodium phosphate, 4000 units of chymotrypsin, 80,000 units of gentamicin sulfate in 20 mL normal saline at 1 mL/min
Number of subjects: 115
Study 19155999 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (100 mg/m(2) d(1), d(8), d(15)) plus gemcitabine (1250 mg/m(2) d(1) and d(8), every 4 weeks) - Arm B
Number of subjects: 228
Study 19155999 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m(2), d(1)) and gemcitabine (1250 mg/m(2), d(1) and d(8), every 3 weeks) - Arm A
Number of subjects: 228
Study 17637394 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining parametric Lyman probit with nonparametric decision trees
Number of subjects: 234
Study 17637394 — intervention group
Group type: COMPARATOR
Intervention: LNTCP
Number of subjects: 234
Study 15110616 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (group A)
Number of subjects: 40
Study 15110616 — intervention group
Group type: COMPARATOR
Intervention: ATG-fresenius (group B)
Number of subjects: 40
Study 11822009 — intervention group
Group type: EXPERIMENTAL
Intervention: Expandable metal stents or ablative therapy
Number of subjects: 0
Study 11822009 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection
Number of subjects: 0
Study 11822009 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 0
Study 9846778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum dosage of 3600 mg/d)
Number of subjects: 229
Study 9846778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 8087332 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO2 followed by 0.3 ppm O3
Number of subjects: 21
Study 8087332 — intervention group
Group type: COMPARATOR
Intervention: Air exposure followed by 0.3 ppm O3
Number of subjects: 21
Study 29205157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 1250
Study 29205157 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 1250
Study 27592206 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up approach with intention to avoid surgery
Number of subjects: 40
Study 27592206 — intervention group
Group type: COMPARATOR
Intervention: Step-up approach as a bridge to surgery
Number of subjects: 40
Study 27592206 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 40
Study 24593836 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) treatment
Number of subjects: 60
Study 24593836 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival scaling treatment
Number of subjects: 60
Study 24593836 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 60
Study 22172433 — intervention group
Group type: EXPERIMENTAL
Intervention: LibiGel (low-dose testosterone gel)
Number of subjects: 0
Study 22172433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20823282 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (arm A)
Number of subjects: 19
Study 20823282 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg plus atazanavir 400 mg once daily (arm B)
Number of subjects: 19
Study 18434927 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring with electrodes placed into orbicularis oculi (1.5‐cm spacing; n = 15)
Number of subjects: 30
Study 18434927 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial nerve monitoring with electrodes placed into orbicularis oris (1.0‐cm spacing; n = 15)
Number of subjects: 30
Study 16395096 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (2 doses, 6-8 weeks apart)
Number of subjects: 494
Study 16395096 — intervention group
Group type: COMPARATOR
Intervention: MMR+V group (1 dose of MMR and 1 dose of varicella, followed by a second dose of MMR at 6-8 weeks later)
Number of subjects: 494
Study 16395096 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (after first dose)
Number of subjects: 494
Study 16395096 — intervention group
Group type: COMPARATOR
Intervention: MMR+V group (after first dose)
Number of subjects: 494
Study 16395096 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (after second dose)
Number of subjects: 494
Study 16395096 — intervention group
Group type: COMPARATOR
Intervention: MMR+V group (after second dose)
Number of subjects: 494
Study 12897596 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical power and sample size in studies published in 1997 in the American and British volumes of the Journal of Bone and Joint Surgery, and in Clinical Orthopaedics and Related Research
Number of subjects: 0
Study 12897596 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized control trials in the journals examined
Number of subjects: 0
Study 10816184 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of sedative infusions
Number of subjects: 128
Study 10816184 — intervention group
Group type: COMPARATOR
Intervention: Control group (interruption at clinician's discretion)
Number of subjects: 128
Study 8622612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous endothelin-1
Number of subjects: 6
Study 8622612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg) pretreatment before endothelin-1 infusion
Number of subjects: 6
Study 1595824 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow orthosis
Number of subjects: 2
Study 1595824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hand splints
Number of subjects: 2
Study 1595824 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 2
Study 3883964 — intervention group
Group type: EXPERIMENTAL
Intervention: UV filter on the operating microscope
Number of subjects: 297
Study 3883964 — intervention group
Group type: COMPARATOR
Intervention: No UV filter on the operating microscope
Number of subjects: 297
Study 31728623 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-DOMS protocol in extension
Number of subjects: 20
Study 31728623 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-DOMS protocol
Number of subjects: 20
Study 29654204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel cessation (any type)
Number of subjects: 1830
Study 29654204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel disruption
Number of subjects: 1830
Study 29654204 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel cessation (crossover or discontinuation)
Number of subjects: 1830
Study 26319955 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil (PO) 3 times daily for 4 weeks
Number of subjects: 72
Study 26319955 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times daily for 4 weeks
Number of subjects: 72
Study 25694037 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-7 (180 µg MenaQ7/day)
Number of subjects: 244
Study 25694037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 22869206 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizenship intervention
Number of subjects: 114
Study 22869206 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 114
Study 20431383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccination in low-birth-weight babies
Number of subjects: 0
Study 20431383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early measles vaccination
Number of subjects: 0
Study 20431383 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered timing of DTP vaccination
Number of subjects: 0
Study 19719770 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer home-visiting support from Home-Start
Number of subjects: 0
Study 19719770 — intervention group
Group type: COMPARATOR
Intervention: Case-matched controls (no volunteer support)
Number of subjects: 0
Study 19719770 — intervention group
Group type: COMPARATOR
Intervention: Those offered but not receiving support
Number of subjects: 0
Study 15696079 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast, 80 mg twice daily for 6 weeks
Number of subjects: 25
Study 15696079 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 15696079 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 25
Study 12854927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg intravaginally every 3 h for a maximum of 24 h)
Number of subjects: 200
Study 12854927 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert (10 mg every 12 h for a maximum of 24 h)
Number of subjects: 200
Study 12854927 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 200
Study 12854927 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal insert
Number of subjects: 200
Study 12854927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 200
Study 10543411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg glimepiride
Number of subjects: 24
Study 10543411 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg glimepiride
Number of subjects: 24
Study 10543411 — intervention group
Group type: COMPARATOR
Intervention: 1 mg glibenclamide
Number of subjects: 24
Study 10543411 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 24
Study 8911107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (CTC) incorporating cyclophosphamide, thiotepa, and carboplatin with autologous PBSC support.
Number of subjects: 70
Study 8911107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (CTC) with autologous PBSC support.
Number of subjects: 70
Study 1671188 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12
Study 1671188 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 12
Study 6129380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet for 6 weeks
Number of subjects: 59
Study 6129380 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet for 14 weeks (Control)
Number of subjects: 59
Study 6129380 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverted to omnivorous diet after vegetarian diet
Number of subjects: 59
Study 31298171 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation therapy (CCRT)
Number of subjects: 311
Study 31298171 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 311
Study 30131318 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended therapy
Number of subjects: 350
Study 30131318 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 350
Study 26707418 — intervention group
Group type: EXPERIMENTAL
Intervention: 360° ALPI
Number of subjects: 80
Study 26707418 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (Travoprost 0.004%)
Number of subjects: 80
Study 24754066 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate eradication therapy during treatment for CHD
Number of subjects: 112